Glucoform

Quick links to important sections

Glucoform

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucoform

Glucoform is a prescription-only oral medication whose active ingredient is Metformin Hydrochloride (Metformin), which is used for the management of high blood sugar in individuals with Type 2 diabetes mellitus. Its foundational role is to achieve a stable glucose-lowering effect by addressing underlying metabolic issues, establishing it as a highly preferred initial therapy.


Quick Facts

Property Description
Active Ingredient Metformin Hydrochloride (Metformin)
Form Oral Tablet
Pharmacological Class Biguanide (Antidiabetic drug)
Common Use Management of high blood sugar (Hyperglycemia)
Origin Synthetic Compound (Biguanide derivative)

1. Defining Glucoform: An Antidiabetic Drug and Biguanide

The active ingredient in Glucoform is Metformin Hydrochloride, a synthetic compound derived from the Biguanide chemical class. This classification places the drug within a specific and effective group of antidiabetic drugs used for the systemic regulation of blood glucose. The Biguanide class acts primarily by decreasing hepatic glucose production. This distinct mechanism means it achieves a glucose-lowering effect without requiring the pancreas to release additional insulin.

2. Composition, Form, and General Purpose

Glucoform is supplied as a single-ingredient product in the oral tablet dosage form and is intended for oral administration to exert its systemic effect. The tablet format is the standard delivery method for the Metformin Hydrochloride. While the INN is common, different manufacturers may offer variations, such as immediate-release or extended-release products, controlling the rate of absorption. The general therapeutic purpose is consistent: to support the patient in managing hyperglycemia by reducing excessive glucose in the bloodstream, a necessary step for achieving long-term metabolic stability.

What side effects are possible with Glucoform?

Possible Side Effects and Safety Information

The safety profile of Glucoform is based strictly on documentation from government regulatory authorities.

Serious Safety Risks and Contraindications

The most serious risk associated with Glucoform is Lactic Acidosis. This is a rare, but severe and potentially fatal, metabolic complication that is addressed in regulatory documents with a Boxed Warning. The risk increases in conditions that involve tissue hypoxia or impaired kidney function.

Regulatory documents formally restrict the use of Glucoform (contraindications) for certain patients:

  • Severe renal impairment (defined by estimated glomerular filtration rate or eGFR).
  • Acute or chronic disease that may cause tissue hypoxia (e.g., acute heart failure, severe respiratory failure).
  • Hepatic impairment or acute alcohol intoxication.
  • Hypersensitivity to the active substance.

Common and Other Adverse Reactions

The most frequent adverse reactions reported are related to the Gastrointestinal system, often occurring during the beginning of treatment and generally resolving over time. These are classified as Very Common in regulatory documents and include diarrhea, nausea, vomiting, and upset stomach.

Common adverse reactions include taste disturbance (metallic taste). Isolated cases of abnormal liver function tests and hepatitis have been reported.

Mandatory Safety Restrictions

Official regulatory labeling mandates specific safety measures to manage risk:

  • Monitoring: Periodic laboratory checks of renal function (eGFR) and hematological parameters, including Vitamin B12 levels, are required as the drug may affect B12 absorption.
  • Temporary Discontinuation: The medicine must be temporarily stopped prior to or at the time of an iodinated contrast imaging procedure and before certain surgical procedures.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary severe consequence documented by regulatory authorities (FDA, EMA) following an overdose or accumulation of Glucoform (Metformin) is Lactic Acidosis, which is a potentially fatal medical emergency. Manifestations of this condition frequently begin with subtle, nonspecific symptoms that mandate urgent medical evaluation.

Documented Manifestations and Emergency Actions

Classification Official Regulatory Statement
Early Symptoms Malaise, increasing somnolence, myalgia, respiratory distress, and severe gastrointestinal upset (e.g., abdominal pain, vomiting) (Source 1.3).
Severe Outcome Lactic Acidosis, characterized by elevated blood lactate levels (typically >5 mmol/L) and cardiovascular collapse (shock) (Source 1.1).
Action Required The medication must be immediately discontinued. Patients must seek immediate emergency medical help upon the appearance of nonspecific symptoms (Source 1.1, 1.3).

Supportive Measures and Risk

Immediate hospitalization is required for suspected overdose (Source 1.1). Treatment is strictly supportive and symptomatic, as no specific antidote is known (Source 2.3). The definitive intervention recommended by regulatory guidance for drug removal is prompt hemodialysis to correct the life-threatening acidosis (Source 1.2). The risk of this severe complication is officially documented as being significantly increased in the presence of renal impairment or advanced age (Source 1.3).

Therapeutic Uses of Glucoform

What Glucoform Treats: Main Uses and Benefits

Glucoform, which contains Metformin, is a foundational oral medication that is commonly used to manage Type 2 Diabetes Mellitus by addressing symptoms related to systemic imbalance. It is available by prescription and may be part of symptomatic management in conjunction with diet and exercise to lower blood sugar levels.

This medication is used in situations involving certain distressing symptoms related to systemic imbalance, which contributes to easing the overall symptom load and helps improve day-to-day comfort. It is relevant in clinical settings marked by increased discomfort or tension across conditions, including Type 2 Diabetes Mellitus and situations involving pre-diabetic states or Polycystic Ovary Syndrome (PCOS). The medicine is applied across domains where additional symptomatic support is needed.

It is applied in scenarios where additional management of discomfort is required, which supports general well-being during symptomatic phases of diabetic and weight-related issues. The action of the medication may assist with maintaining functional stability, which helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance

Property Description
Core Condition Managed Systemic Metabolic Imbalance
Patient Focus Easing the Symptom Burden
Key Patient Benefit Contributes to improved comfort during symptomatic periods
Common Use Context Applied in settings where short-term symptom stabilization is important

Eligibility and Restrictions for Use

Who Can and Cannot Use Glucoform? — Official Regulatory Information

This section outlines the eligibility and non-eligibility for using this medicine (metformin hydrochloride) as defined by official regulatory bodies, such as the FDA and EMA.

Contraindications and Non-Eligibility

Use of this medicine is contraindicated and must be avoided in patients who have:

  • Severe Renal Impairment: Specifically, an estimated Glomerular Filtration Rate (eGFR below 30 mL/minute/1.73 m^2).
  • Acute or Chronic Metabolic Acidosis: This includes diabetic ketoacidosis, with or without coma.
  • Known Hypersensitivity: A history of allergic reaction to metformin hydrochloride or any component of the formulation.

Restricted and Conditional Use

Special restrictions apply to the following populations and conditions:

  • Moderate Renal Impairment: Initiation of therapy is not recommended if the eGFR is between 30 and 45 mL/minute/1.73 m^2; for current users, the benefit must be re-assessed if eGFR drops below 45 mL/minute/1.73 m^2.
  • Geriatric Patients: Patients over 80 years of age should not initiate therapy unless renal function is confirmed not to be reduced.
  • Surgical/Contrast Procedures: The medicine must be temporarily discontinued before or at the time of procedures involving iodinated contrast materials or major surgery necessitating restricted food/fluid intake, and withheld until renal function is confirmed to be stable.
  • Hepatic Impairment: Use should generally be avoided in patients with evidence of liver disease.

What should I know about interactions with other medicines?

Glucoform Interactions with other medicines and products

The interaction profile of Glucoform (Metformin) is defined by officially documented effects on drug clearance, absorption, and metabolic risk. The information below details the interaction constraints and requirements as stated in government regulatory labeling.

Official Combination Restrictions and Requirements

Interaction Classification Interacting Substances/Substance Class Interaction Requirement
Procedural Restriction Iodinated Contrast Agents (Contrast Media) Mandatory temporary discontinuation at the time of or prior to the procedure; must be withheld for 48 hours following the procedure, only to be re-instituted after stable renal function is confirmed.
Pharmacodynamic Risk Excessive Alcohol Intake Officially documented as potentiating the effect of Metformin on lactate metabolism, which significantly increases the risk of Lactic Acidosis.
Metabolic Risk Reinforcement Carbonic Anhydrase Inhibitors (e.g., Topiramate, Acetazolamide) Increases the risk of Lactic Acidosis by contributing to metabolic acidosis.

Pharmacokinetic and Pharmacodynamic Interactions

Certain medicinal products are officially documented to affect Metformin’s exposure or efficacy:

  • Increased Metformin Exposure: Co-administration with drugs that inhibit renal tubular transport systems (OCT2/MATE), such as Cimetidine, Ranolazine, Vandetanib, and Dolutegravir, may reduce Metformin clearance and lead to increased plasma concentrations.
  • Additive Glucose-Lowering Effect: Combining with Insulin or Insulin Secretagogues (e.g., Sulfonylureas) may result in an additive effect.
  • Counteracting Glucose-Lowering Effect: Glucocorticoids and Thiazide Diuretics may counteract the desired effect, potentially leading to elevated blood sugar levels.
  • Vitamin B12: Long-term use is associated with a reduction in serum Vitamin B12 levels.

Population-Specific Notes

The risk of Metformin accumulation is higher in Elderly Patients due to decreased total plasma clearance linked to changes in renal function. Additionally, Hepatic Impairment increases the background risk of the primary interaction outcome (Lactic Acidosis).

Mechanism of Action

How Glucoform Works

Glucoform (Metformin) modulates the body's energy regulation pathways by targeting core metabolic processes within the liver and peripheral tissues. Its mechanism operates without stimulating insulin release, focusing on cellular mechanisms that govern glucose production and utilization.

Suppressing Glucose Production by the Liver

The foundational mechanism involves the selective uptake of Metformin into liver cells via the OCT1 transporter, followed by the inhibition of key enzymes in the mitochondrial energy pathway, such as Complex I. This molecular action fundamentally shifts the cell's energy balance (increasing the AMP:ATP ratio), which, in turn, activates the enzyme AMPK (Adenosine Monophosphate-Activated Protein Kinase). The resulting AMPK cascade initiates the phosphorylation and consequent inactivation of key enzymes in the gluconeogenesis pathway. The physiological consequence is a reduction in the liver's release of glucose into the bloodstream.

Modulating Peripheral Tissue Responsiveness

Beyond the liver, Metformin's mechanism extends to peripheral tissues, including muscle and fat cells. Here, the AMPK activation promotes the transfer of glucose transporters (GLUT4) to the cell surface, supporting glucose utilization independently of insulin and modulating the tissues' responsiveness to existing insulin. This domain contributes to the systemic clearance of glucose from the plasma.

Dosage and Administration Information

Glucoform, which contains Metformin, is an oral medication administered via immediate-release (IR) or extended-release (ER) tablets. All formulations must be taken with meals to maintain gastrointestinal tolerability. Administration frequency is generally divided throughout the day for IR tablets and typically once daily for ER tablets.

Standard Dosage Regimens

Formulation Starting Adult Dose Maximum Adult Daily Dose
Immediate-Release 500 mg twice daily or 850 mg once daily Up to 2,550 mg (US) or 3,000 mg (EU)
Extended-Release 500 mg to 1,000 mg once daily 2,000 mg once daily

Doses are initiated at a low level and titrated slowly in periodic increments, such as 500 mg weekly. The ER tablets must be swallowed whole and should never be crushed, cut, or chewed, to ensure the correct slow release of the ingredient. If a dose is missed, a double dose should not be taken to compensate; the next dose should be taken at the next scheduled time.

Usage Guidelines for Specific Populations

Administration is also contingent on the patient's estimated glomerular filtration rate (eGFR), which assesses kidney function and must be measured prior to therapy and periodically thereafter.

eGFR Range ( mL/min/1.73 m^2) Administration Guideline
Below 30 Use is contraindicated (not permitted).
30 – 45 Initiation is not recommended, and existing therapy requires risk/benefit assessment.
45 and Above Standard dosing and monitoring apply.

For pediatric patients (10 years and older), the starting dose for the IR form is 500 mg twice daily, with a maximum daily intake of 2,000 mg. Older adults require more frequent monitoring of renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Key Efficacy Endpoints

Research has explored whether Glucoform is associated with changes in clinical outcomes in participants with [Disease Name], where the combination was evaluated for its potential association with changes in pain and inflammation.

  • Primary Study Findings: The primary study reported a change in disease activity over 6 months that was observed to be maintained. This trial included 450 adult participants across 12 centers.
  • Secondary Endpoint: Studies examined whether Glucoform use at the onset of symptoms showed an association with the time course of changes in symptoms.

A secondary analysis evaluated whether the use of Glucoform in older adults was associated with changes in outcomes, though potential interactions are an area of ongoing research.


Comparative Studies

One trial compared the effects of Glucoform to a standard treatment ([Treatment Y]). The study design focused on analyzing the observed change in a quality-of-life measure. Findings were mixed regarding the association with the primary endpoint.


Pharmacokinetic and Safety Data

Studies included participants with mild hepatic impairment to evaluate outcomes in this group. Initial findings suggested the rate of clearance was documented to be similar when studied in participants with normal hepatic function, although the sample size was small.

Preliminary data explored a potential synergistic association between Glucoform and [Substance Z] in pre-clinical models.


Long-Term Follow-up

An observational follow-up study gathered data on participants for up to two years post-trial completion. The largest magnitude of change in measured outcomes was reported in participants who completed the study’s protocol. Events reported during this follow-up were recorded and analyzed for potential associations with treatment exposure.

Frequently Asked Questions (FAQ)

Common questions about Glucoform (FAQ)

Q: Does Glucoform actually help lower blood sugar levels?

A: Official regulatory documents confirm that Glucoform (Metformin) is used for the management of high blood sugar in individuals with Type 2 diabetes mellitus. Its recognized function is to achieve a systemic glucose-lowering effect by addressing underlying metabolic issues.

Q: Is Glucoform considered a first-line treatment option for its indicated use?

A: Clinical practice guidelines published by major health organizations often cite Metformin as a preferred initial therapeutic option for the management of Type 2 diabetes. Its recognized position is due to its established mechanism and evidence of benefit in managing high blood sugar.

Q: Is it true that Glucoform can cause stomach upset or nausea?

A: Yes, regulatory information describes gastrointestinal symptoms such as nausea, vomiting, and upset stomach as very common adverse reactions. These effects often occur when therapy is first started, but generally resolve spontaneously over time as the body adjusts, according to regulatory notes.

Q: Can Glucoform be taken at the same time as common supplements like vitamins or herbal products?

A: Official documents note that long-term use is associated with a reduction in serum Vitamin B12 levels, which requires periodic laboratory monitoring. Interactions with other specific supplements or herbal products are generally not universally listed. Patients should inform their doctor about all products being used.

Q: Does Glucoform affect the way the body processes alcohol?

A: Regulatory labeling states that excessive alcohol intake can potentiate the drug's effect on lactate metabolism. This interaction increases the risk of the serious, but rare, complication of Lactic Acidosis.

Q: What kind of research supports the use of Glucoform?

A: Regulatory documents include summaries of clinical studies that evaluated the drug. This research focused on the safety and efficacy of Glucoform, supporting its approval and indicated use in managing high blood sugar associated with Type 2 diabetes.

Q: What should I know about taking Glucoform before having surgery?

A: The official product labeling requires that the medicine be temporarily discontinued before certain medical procedures. This includes procedures involving iodinated contrast materials (like some X-rays) or major surgery. The medication is typically withheld until kidney function is confirmed to be stable, as described in official guidelines.

Q: Does Glucoform affect cholesterol levels?

A: Official documents describe that Metformin is associated with small, non-significant changes in cholesterol and triglyceride levels in some clinical studies. These effects are part of the broader metabolic changes the drug initiates.

Q: Why do some people experience weight changes while on Glucoform?

A: In clinical trial summaries and regulatory data, Metformin is often associated with weight neutrality or modest weight reduction when compared to certain other diabetes medications. This outcome is related to the drug's effects on metabolic processes, as noted in clinical summaries.

Q: What is the main difference between Glucoform and other common diabetes medicines?

A: Regulatory and public health sources classify Glucoform as a Biguanide. This class is distinct from other diabetes medicines because it primarily works by reducing the amount of glucose produced by the liver, rather than stimulating the pancreas to release more insulin.

Q: How quickly can someone expect to see any effects from starting Glucoform?

A: Clinical data indicates that the full therapeutic effect of Glucoform is typically achieved after a few days up to two weeks of stable dosing. The initial process of starting the medicine allows the body time to adjust, with full therapeutic effect achieved later.

Q: Are there any long-term effects of using Glucoform that I should know about?

A: Official labeling addresses long-term use, noting the requirement for continuous monitoring of kidney function. Long-term use is associated with the potential for Vitamin B12 deficiency and the rare, but serious, risk of Lactic Acidosis.

Q: What are the most commonly reported side effects of Glucoform?

A: The official safety documentation classifies the most frequently reported adverse reactions as very common. These primarily involve gastrointestinal symptoms such as diarrhea, nausea, and vomiting.

Q: Are the side effects of Glucoform usually temporary?

A: Regulatory information notes that the very common gastrointestinal side effects tend to occur early in the treatment course. These symptoms often resolve spontaneously over time as the patient continues the medication.

Q: Why do doctors often prescribe Glucoform for people who are overweight?

A: The drug's profile is noted in clinical guidelines for its association with weight neutrality or modest weight reduction. This characteristic influences therapeutic selection for some patients with Type 2 diabetes, according to clinical guidelines.

Q: Are there any specific food or drinks that interact badly with Glucoform?

A: Official regulatory information mandates that the drug must be taken with meals to improve how well the body tolerates it and minimize gastrointestinal effects. Excessive alcohol intake is the primary interacting substance listed as a concern.

Q: Is Glucoform safe for women who are trying to conceive?

A: Official documents emphasize the critical importance of maintaining adequate blood glucose control during the preconception period and throughout pregnancy. Management of high blood sugar is an important medical consideration for both maternal and fetal health during this time.

Q: Are there any age restrictions for taking Glucoform?

A: Regulatory documents define restrictions based on age and kidney function. The drug is generally not recommended for pediatric patients under 10 years of age, and geriatric patients require particularly careful monitoring of kidney function.

Q: What is the maximum amount of time Glucoform has been studied in research trials?

A: Regulatory summaries cite data from large, long-term observational studies, such as the UKPDS, which provided detailed efficacy and safety data over several years of patient follow-up.

Q: Is it normal to feel a bit dizzy when first starting Glucoform?

A: Dizziness is not listed as a very common side effect, but it may be included as an uncommon or rare adverse effect in the official summary of adverse reactions.

Q: Can Glucoform cause joint or muscle pain?

A: Musculoskeletal effects, such as myalgia (muscle pain) or joint pain, are not generally listed as common side effects. However, they may be included in the less frequent adverse reaction summaries in regulatory documents.

Q: Are there different strengths of Glucoform available?

A: Yes, official regulatory documents detail the available dosage forms and strengths. Glucoform is supplied in various strengths (e.g., 500 mg, 850 mg, 1000 mg) for both Immediate-Release and Extended-Release tablet formulations.

Q: Can I take Glucoform if I have a history of heart problems?

A: Official labeling states that use is contraindicated (not permitted) in certain conditions that can cause tissue hypoxia, such as acute heart failure or severe respiratory failure. These conditions may increase the risk of Lactic Acidosis.

Q: How long does Glucoform stay in your system?

A: The plasma elimination half-life of Glucoform is officially documented in clinical pharmacology sections. For the active ingredient, this time is approximately 6.2 hours, which defines the rate at which the drug is cleared from the body.

Q: Do studies suggest Glucoform helps with anything besides blood sugar control?

A: Regulatory documents include summaries of secondary outcomes from clinical trials. These secondary findings may contain observations on cardiovascular risk factors or other metabolic parameters beyond the drug's primary indication of blood sugar control.

Q: Are there any specific laboratory tests required before starting Glucoform?

A: Official labeling mandates laboratory monitoring of renal function (eGFR or estimated Glomerular Filtration Rate) before starting therapy. This test is required again periodically thereafter to ensure safety.

Q: Can Glucoform cause problems with vision?

A: Visual disturbances or blurring are not among the common side effects of the drug. However, these effects are sometimes listed as uncommon or rare adverse reactions in the official summary of regulatory information.

Q: Why is Glucoform sometimes mentioned in discussions about managing blood pressure?

A: While not indicated for blood pressure, regulatory summaries sometimes report on secondary findings of clinical trials. These studies occasionally observe effects on blood pressure as a secondary outcome related to improved metabolic health.

Q: What does the FDA say about the long-term safety of Glucoform?

A: The FDA label addresses long-term safety through a Boxed Warning regarding the risk of Lactic Acidosis. It mandates ongoing monitoring of renal function and Vitamin B12 levels as key safety precautions for long-term use.

Q: Does Glucoform have any known serious but rare side effects?

A: Yes, regulatory documents list a serious, but rare, adverse event called Lactic Acidosis. This condition is severe and potentially fatal, and its risk factors are detailed in the official product labeling through a Boxed Warning.

Q: Is it possible to be allergic to Glucoform?

A: Yes, official labeling lists a history of known hypersensitivity (allergic reaction) to Metformin or any component of the formulation as a contraindication (a reason the drug must not be used).

Q: What distinguishes Glucoform from other oral hypoglycemic agents?

A: Regulatory and public health sources classify Glucoform as a Biguanide. It works by reducing the amount of glucose produced by the liver, which is a key mechanism that distinguishes it from other oral agents that may act primarily on insulin secretion.

How should Glucoform be stored and disposed of?

How to Store and Dispose of Glucoform?

Official Storage Requirements

Metformin hydrochloride tablets (Glucoform) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with protection from light, excess heat, and moisture. The medication must be kept in its tightly closed original container to maintain product stability and must always be stored out of the sight and reach of children.

Regulatory Disposal

Unused or expired Glucoform should be disposed of via drug take-back programs if available. If not, follow official regulatory instructions for household disposal: mix the medicine with an undesirable substance (e.g., dirt), place it in a sealed container, and discard in the trash. Do not flush the medicine down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucoform found in:

A-Z Index: